Next 10 |
home / stock / mirm / mirm articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endp...
Monday, Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) announced interim results from two Phase 2b studies evaluating volixibat for primary biliary ...
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confide...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical compa...
Wednesday, The FDA approved Mirum Pharmaceuticals Inc’s (NASDAQ:MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus...
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fe...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline...
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NYSE Market:
Mirum Pharmaceuticals Inc. Website:
Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a new drug application (ND...
2024-06-23 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 16:15:02 ET Evercore ISI analyst issues OUTPERFORM recommendation for MIRM on June 17, 2024 03:27PM ET. The previous analyst recommendation was Outperform. MIRM was trading at $32.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...